The Facial Injectable Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

New York, NY -- (SBWire) -- 03/10/2017 --Facial Injectable Market: Drivers and Challenges

The global market for facial injectable is expected to be driven by increasing demand from middle age & growing urban population and raising esthetic standards. The target age group for these products is women age between35 to 60 years. However, both men and women are using these products to achieve and retain the youthful appearance. Adoption of dermal fillers across the world is different due to obvious differences in factors such as geographic location, life style and socioeconomic conditions, ethnicity etc. Legal and regulatory issues and safety concerns of certain injectable products such as boltulinum toxin A will remain substantial restraints for the global facial injectable market. In the U.S., injectable facial fillers are considered as Class III medical device, meaning they pose high risk to patient safety.

As on now, facial injectable are approved for use in indications such as correction of moderate to severe facial folds and wrinkles, lip augmentation and dermal implantation for correction of perioral rhytids, cheek augmentation, correction of nasolabial folds, correction of acne and depressed cutaneous scars etc. However, the off-label use of facial injectable in countries such as Japan, India, and some of the European countries would drive the growth of global market for facial injectable.

Facial Injectable Market: Key Players

Some of the players operating in global facial injectable market are Advanced Dermatology, Merz, Inc., Galderma Laboratories, L.P., ColBar LifeScience Ltd., Allergan, Plc., Valeant Pharmaceuticals North America LLC., Sanofi Biosurgery Inc. (Sanofi), Anika Therapeutics, Inc., Suneva Medical, Inc. and others. Distribution agreements between the global and regional players in the global facial injectable market is emerging as the prominent trend overtime. For instance, Galderme Laboratories distributed Valeant Pharmaceuticals' Restylane line of products in the U.S. and Canada. Companies are employing strategic advertisement campaigns involving leading film stars to attract the consumers.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14350

Facial Injectable Market: Regional Overview

On the basis of regional presence, global facial injectable market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Europe is expected to lead the global market while North America is expected to hold second largest market share in global facial injectable market. In the U.S. facial injectable such as dermal fillers are considered as a medical device and are covered under prescription products. Whereas in Europe facial injectable are considered as a non-prescription products which allows the widespread use of them. Asia Pacific market for facial injectable is expected to grow at significant CAGR over the forecast period owing to increasing beauty concern among mid-age population.

To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/14350